Compare BTG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | RYTM |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.8B |
| IPO Year | 2007 | 2017 |
| Metric | BTG | RYTM |
|---|---|---|
| Price | $4.58 | $94.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $6.00 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 20.0M | 555.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.08 | $55.34 |
| Revenue Next Year | $28.46 | $86.06 |
| P/E Ratio | $34.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.31 | $60.99 |
| 52 Week High | $6.29 | $122.20 |
| Indicator | BTG | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 63.09 |
| Support Level | $4.32 | $82.43 |
| Resistance Level | $4.89 | $100.69 |
| Average True Range (ATR) | 0.19 | 4.46 |
| MACD | 0.03 | 0.65 |
| Stochastic Oscillator | 78.43 | 82.82 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.